



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 211/34	A1	(11) International Publication Number: WO 97/28124 (43) International Publication Date: 7 August 1997 (07.08.97)
(21) International Application Number: PCT/GB97/00281 (22) International Filing Date: 31 January 1997 (31.01.97) (30) Priority Data: 9602174.6 2 February 1996 (02.02.96) GB 9618836.2 10 September 1996 (10.09.96) GB (71) Applicant: MEDEVA EUROPE LIMITED [GB/GB]; 10 St. James's Street, London SW1 1EF (GB). (72) Inventors: LANGSTON, Marianne; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). ZAVAREH, Hooshang, Shahriari; Chiroscience Limited, Cambridge Science Park, Milton Road, Cambridge CB4 4WE (GB). (74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PROCESS FOR THE PREPARATION OF D-THREO-(R,R)-METHYL PHENIDATE AND RECYCLING OF UNDESIREN ENANTIOMERS BY EPIMERISATION (57) Abstract A process for obtaining a single enantiomer, <i>d</i> or <i>l</i> , of <i>threo</i> -methylphenidate, comprises resolution of a mixture of the enantiomers; racemisation of the unwanted enantiomer, to give a mixture of all four stereoisomers; and separation of the <i>erythro</i> stereoisomers, to leave the said mixture of enantiomers for resolution.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PROCESS FOR THE PREPARATION OF D-THREO-(R,R)-METHYL PHENIDATE AND
RECYCLING OF UNDESIRE ENANTIOMERS BY EPIMERISATION

Field of the Invention

This invention relates to an economic process for the manufacture of a single isomer of methylphenidate.

5 Background to the Invention

Methylphenidate is a therapeutic agent that is widely used in the treatment of attention-deficit hyperactivity disorder. It is a controlled substance.

Methylphenidate was first prepared as a mixture of the *erythro* [*R*S**] and
10 *threo* [*R*R**] racemates. US-A-2957880 discloses studies upon the two racemic mixtures, which revealed that the therapeutic activity resides in the *threo* diastereoisomer. It is now considered that it is the *d-threo* [or (*R,R*)] enantiomer that has the preferred therapeutic activity. Uses of this enantiomer are disclosed in PCT/GB96/01688, PCT/GB96/01689 and PCT/GB96/01690, the contents of which are incorporated herein by reference.

15 The resolution of *threo*-methylphenidate can be achieved using the expensive resolving agent 1,1'-binaphthyl-2,2'-diyl hydrogen phosphate, a process first reported by Patrick *et al*, The Journal of Pharmacology and Experimental Therapeutics, 241:152-158 (1987). A more efficient resolution, using a *O,O'*-diaroyltartaric acid, is disclosed in PCT/GB97/00185, the contents of which are incorporated by
20 reference; in particular, the use of *O,O'*-di-*p*-toluoyltartaric acid allows the diastereoisomeric salts to be very readily separated.


In an alternative approach, disclosed in US-A-2957880, the amide of *erythro*-methylphenidate (i.e. as -CONH₂ instead of -CO₂Me) is resolved using tartaric acid. However, this resolution must be followed by amide hydrolysis, and equilibration
25 at the benzylic centre, to give the *threo* isomer of the carboxylic acid (ritalinic acid) which is esterified. US-A-2957880 describes a general process for conversion of *erythro* diastereoisomers to *threo* diastereoisomers, using alkali and elevated temperature.

In order to establish an economic resolution process, it is highly desirable to
30 be able to recycle the unwanted enantiomer into the resolution by way of a racemisation. This becomes especially important when the resolution is performed late in a synthesis. An example of such a resolution and racemisation procedure is

in the case of naproxen where the single stereogenic carbon centre, which is benzylic and further activated by the carboxylate, is readily racemised. However, in the case of methylphenidate, there are two stereogenic centres. While one centre is similarly benzylic and can be epimerised as indicated in US-A-2957880, that converts the material into a mixture of two diastereoisomers and not into the racemate that is required for recycling.

Summary of the Invention

This invention is based on the discovery of methods to effect racemisation of both chiral centres of methylphenidate. This process gives an optically inactive mixture of stereoisomers in which equilibrium may favour the *threo* isomer; the result is that undesired enantiomer is converted predominantly into the racemate of the *threo* isomer which can then be reintroduced into the resolution. The overall process of a combination of resolution and racemisation that may allow complete conversion into the required isomer is outlined in Scheme 1. The *erythro* isomer that may remain after the racemisation can be separated by conventional methods such as crystallisation at this stage and subjected further to the epimerisation conditions defined below. Alternatively, it can be recycled after passage through resolution of the *threo* isomer.



Scheme 1

Description of the Invention

In Scheme 1, the group X may be the $-CO_2Me$ function of methylphenidate. Resolution of this compound may be carried out by generally known procedures, e.g. by formation of a diastereoisomeric salt with a chiral acid. Alternatively, the
5 resolution may be a biotransformation that modifies the group X in one enantiomer so that the enantiomers (of different compounds) are then readily separated.

This invention includes the means to effect racemisation at both stereogenic centres. It has been discovered that such racemisation can be carried out by way of activation at the piperidine nitrogen, which probably promotes a fragmentation of the
10 ring, although the exact mechanism has not been ascertained. The putative olefinic intermediate has no chirality and recloses to a racemic mixture.

There are various ways in which the nitrogen may be activated, to promote the elimination-addition mechanism. One approach is treatment with an acid, for example a carboxylic acid, at a sufficiently high temperature, such as heating with
15 propionic acid, e.g. under reflux. This reaction is suitably conducted in an inert solvent such as toluene. The racemisation can optionally be accelerated by the judicious addition of amounts of additives such as water or inorganic salts that will favour the charge separation in the transition state of the elimination. This reaction may also be promoted by the addition of an aldehyde or ketone (e.g. butyraldehyde
20 or 2-cyclohexen-1-one).

As indicated above, conditions are known that will epimerise *erythro*-ritalinic acid at the benzylic centre only. On the basis of the evidence herein, it will readily be apparent to the man of ordinary skill in the art that conditions can be adopted, in
25 order to give all 4 stereoisomers of methylphenidate, by racemisation at both chiral centres.

Following racemisation, and prior to resolution, it is necessary to enrich the mixture in the *threo* enantiomers. For example, the racemic methylphenidate is hydrolysed, e.g. using base such as alkali metal hydroxide. This can be done such that there is also epimerisation. Work-up with acid gives predominantly *threo*
30 ritalinic acid ($X = CO_2H$), which can be esterified, e.g. by reaction with methanol, to give the appropriate substrate for resolution.. Alternatively, the *erythro* isomers

can be separated by precipitation, and then subjected to sequential epimerisation, esterification and resolution.

The following experiment was conducted in order to illustrate the feasibility of racemisation.

5 Propionic acid (2 ml) was added to a solution of *d-threo*-methylphenidate (5 g) in toluene (25 ml), and the solution was heated under reflux for 4 hours. The mixture was then cooled to ambient temperature, and was rinsed with dilute sodium carbonate and then with water. The organic phase was separated and dried with magnesium sulphate and evaporated under reduced pressure. The resulting oil (4.3
10 g) was analysed by chiral HPLC which indicated the presence of all 4 stereoisomers of methylphenidate in roughly equal proportions.

In order to preparing *d-threo*-methylphenidate by an efficient recycling process, the following protocol is adopted:

- 15 1) Resolve *dl-threo*-methylphenidate by the procedure described in the Example of PCT/GB97/00185.
- 2) Racemise the residual *l-threo*-methylphenidate by the procedure described in the experiment above.
- 3) Hydrolyse the resultant racemic methylphenidate using 50% KOH and heating at reflux.
- 20 4) Esterify the resultant mixture of enantiomers, enriched in *dl-threo*-ritalinic acid, by reaction with MeOH and HCl.
- 5) Isolate the free base and recrystallise, to obtain essentially pure *dl-threo*-methylphenidate, suitable as a feedstock for resolution into constituent enantiomers.

CLAIMS

1. A process for obtaining a single enantiomer, *d* or *l*, of *threo*-methylphenidate, which comprises resolution of a mixture of the enantiomers; racemisation of the unwanted enantiomer, to give a mixture of all four stereoisomers; and separation of
5 the *erythro* stereoisomers, to leave the said mixture of enantiomers for resolution.
2. A process according to claim 1, wherein the single enantiomer obtained is the *d-threo* isomer, i.e. the isomer of (*R,R*) absolute configuration.
3. A process according to claim 1 or claim 2, wherein the racemisation comprises heating the unwanted enantiomer with a carboxylic acid.
- 10 4. A process according to any preceding claim, wherein the separation is conducted following hydrolysis of the mixture of stereoisomers, to give ritalinic acid, and before or after re-esterification of the acid.
5. A process according to claim 4, which additionally comprises equilibrating the product of hydrolysis such that the *threo* diastereoisomer is preferentially
15 obtained.
6. A process according to any preceding claim, wherein the resolution is conducted using a chiral acid.
7. A process according to claim 6, wherein the acid is *O,O'*-diaroyltartaric acid.

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/GB 97/00281

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D211/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2 957 880 A (R. ROMETSCH) 25 October 1960 cited in the application see the whole document ---	1-7
A	J. ORG. CHEM., vol. 48, no. 6, 1983, pages 843-846, XP000604702 S. YAMADA ET. AL.: "Method for the Racemization of Optically Active Amino Acids" see the whole document --- -/--	1-7



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

8 April 1997

Date of mailing of the international search report

16. 04. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Kissler, B

INTERNATIONAL SEARCH REPORT

Inter. Application No
PCT/GB 97/00281

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 107, no. 3, 20 July 1987 Columbus, Ohio, US; abstract no. 17704, PATRICK, KENNERLY S. ET AL: "Pharmacology of the enantiomers of threo-methylphenidate" XP002029010 cited in the application see abstract & J. PHARMACOL. EXP. THER. (1987), 241(1), 152-8 CODEN: JPETAB;ISSN: 0022-3565, 1987,	1-7
A	--- CHEMICAL ABSTRACTS, vol. 83, no. 13, 29 September 1975 Columbus, Ohio, US; abstract no. 114219, YAKHONTOV, L. N. ET AL: "Methyl threo-.alpha.-phenyl-.alpha.-(2-piperidyl) acetate hydrochloride" XP002029011 see abstract & SU 466 229 A (ORDZHONIKIDZE, S., ALL-UNION SCIENTIFIC-RESEARCH CHEMICAL- PHARMACEUTI) -----	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/GB 97/00281

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2957880 A	25-10-60	NONE	